14 results on '"Petroziello, M."'
Search Results
2. Abstract No. 130 Comparing Survival Outcomes and Toxicities of 90Y Radioembolization of Colorectal Cancer Metastatic to the Liver Between Patients Older and Younger than 70: Analysis from the RESiN Registry (NCT02685631)
- Author
-
Bishay, S., primary, Emmons, E., additional, Du, L., additional, Krebs, H., additional, Gandhi, R., additional, Collins, Z., additional, O'Hara, R., additional, Akhter, N., additional, Wang, E., additional, Grilli, C., additional, Brower, J., additional, Peck, S., additional, Petroziello, M., additional, Aal, A. Abdel, additional, Golzarian, J., additional, Kennedy, A., additional, Matsuoka, L., additional, Sze, D., additional, and Brown, D., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Abstract No. 80 Progression and Survival Outcomes of Hepatocellular Carcinoma (HCC) Patients within Milan Criteria Following 90Y Radioembolization Using the Radiation-Emitting SIR-Spheres in Non-Resectable Tumor (RESiN) Registry NCT 02685631
- Author
-
Park, S., primary, Du, L., additional, Petroziello, M., additional, Kouri, B., additional, Brower, J., additional, Lee, J., additional, Golzarian, J., additional, Vaheesan, K., additional, Sze, D., additional, Kennedy, A., additional, Matsuoka, L., additional, and Brown, D., additional
- Published
- 2023
- Full Text
- View/download PDF
4. Abstract No. 1 ▪ ABSTRACT OF THE YEAR Survival outcomes and toxicities following Y-90 radioembolization of colorectal cancer metastatic to the liver: 498-patient analysis from the RESiN registry (NCT: 02685631)
- Author
-
Emmons, E., primary, Krebs, H., additional, Gandhi, R., additional, Collins, Z., additional, O’Hara, R., additional, Akhter, N., additional, Wang, E., additional, Grilli, C., additional, Brower, J., additional, Peck, S., additional, Petroziello, M., additional, Aal, A. Abdel, additional, Golzarian, J., additional, Kennedy, A., additional, Matsuoka, L., additional, Sze, D., additional, and Brown, D., additional
- Published
- 2022
- Full Text
- View/download PDF
5. Abstract No. 32 Multi-institutional review of patients receiving Y-90 transarterial radioembolization (TARE) with hepatic tumors status post partial hepatectomy
- Author
-
Rohr, A., primary, Collins, Z., additional, Hodson, A., additional, Zhang, K., additional, Krebs, H., additional, Ghandi, R., additional, O’Hara, R., additional, Akhter, N., additional, Wang, E., additional, Grilli, C., additional, Brower, J., additional, Peck, S., additional, Petroziello, M., additional, Aal, A. Abdel, additional, Golzarian, J., additional, and Brown, D., additional
- Published
- 2022
- Full Text
- View/download PDF
6. Abstract No. 196 Overall survival and toxicities of advanced hepatocellular carcinoma (HCC) Barcelona clinic liver cancer C (BCLC-C) patients following Y-90 radioembolization: assessment from the RESiN Registry (NCT: 02685631)
- Author
-
Goswami, P., primary, Adeniran, O., additional, Frantz, S., additional, Matsuoka, L., additional, Du, L., additional, Gandhi, R., additional, Collins, Z., additional, Matrana, M., additional, Petroziello, M., additional, Brower, J., additional, Sze, D., additional, Kennedy, A., additional, Golzarian, J., additional, Wang, E., additional, and Brown, D., additional
- Published
- 2022
- Full Text
- View/download PDF
7. Abstract No. 115 Demographics and outcomes following Y90 radioembolization of hepatocellular carcinoma at transplant versus non-transplant centers: analysis of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry
- Author
-
Frantz, S., Matsuoka, L., Shahin, I., Vaheesan, K., Petroziello, M., D’Souza, D., Golzarian, J., Matrana, M., Wang, E., Gandhi, R., Collins, Z., Brower, J., Du, Kennedy, A., Sze, D., Lee, J., Adeniran, O., Wong, T., O’Hara, R., Fidelman, N., Shrestha, R., Kouri, B., Hennemeyer, C., Meek, J., Mohan, P., Westcott, M., Siskin, G., and Brown, D.
- Published
- 2021
- Full Text
- View/download PDF
8. Overall survival and toxicity of hepatocellular carcinoma Barcelona Clinic Liver Cancer B patients receiving Y90 radioembolization: analysis of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
- Author
-
Adeniran OR, Nguyen CN, Perez TH, Frantz SK, Matsuoka L, Du L, Gandhi RT, Collins ZS, Matrana MR, Petroziello M, Brower JS, Sze DY, Kennedy AS, Golzarian J, Wang EA, and Brown DB
- Abstract
Background: To evaluate overall survival (OS), progression-free survival (PFS) and toxicity after resin Yttrium-90 (Y-90) radioembolization in Barcelona Clinic Liver Cancer B (BCLC B) hepatocellular carcinoma (HCC) patients using the Bolondi subgroup classification., Methods: A total of 144 BCLC B patients were treated between 2015-2020. Patients were broken into 4 subgroups by tumor burden/liver function tests with 54, 59, 8 and 23 in subgroups 1, 2, 3 and 4. OS and PFS were calculated with Kaplan-Meier analysis with 95% confidence intervals. Toxicities were assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5., Results: Prior resection and chemoembolization were performed in 19 (13%) and 34 (24%) of patients. There were no deaths within 30 days. Median OS and PFS for the cohort were 21.5 and 12.4 months. Median OS was not reached for subgroup 1 at a mean 28.8 months, and was 24.9, 11.0 and 14.6 months for subgroups 2-4 (χ
2 =19.8, P=0.0002). PFS by BCLC B subgroup was 13.8, 12.4, 4.5, and 6.6 months (χ2 =16.8, P=0.0008). The most common Grade 3 or 4 toxicities were elevated bilirubin (n=16, 13.3%) and decreased albumin (n=15, 12.5%). Grade 3 or greater bilirubin (32% vs . 10%, P=0.03) and albumin (26% vs . 10%, P=0.03) toxicity were more common in the subgroup 4 patients., Conclusions: The Bolondi subgroup classification stratifies OS, PFS and development of toxicity in patients treated with resin Y-90 microspheres. OS in subgroup 1 approaches 2.5 years and Grade 3 or greater hepatic toxicity profile in subgroups 1-3 is low., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-22-972/coif). All authors report that the study was supported by Sirtex Medical. RTG is a consultant and speaker for Sirtex Medical and serves as a proctor for Sirtex Medical. Sirtex Medical has funded travel related to these roles. ZSC has received an institutional research grant from Sirtex Medical and serves as a speaker and consultant for Sirtex Medical. JSB is a consultant for Sirtex Medical. DYS has received institutional research grants from Sirtex Medical. He is a consultant and has received support for travel/hotel/meals for meetings with Sirtex Medical. ASK has received institutional support from Sirtex Medical, Bard Medical and ABK Biomedical. JG is a consultant for Sirtex Medical and Boston Scientific. He has also received institutional grant support from Sirtex Medical. EAW is a proctor for Sirtex Medical. DBB has received institutional research support from Sirtex Medical and Guerbet. He has served as a speaker for Cook Medical and a Data Safety Monitor for Bard Medical. The authors have no other conflicts of interest to declare., (2023 Journal of Gastrointestinal Oncology. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
9. Stability of renal parenchymal volume and function during active surveillance of renal oncocytoma patients.
- Author
-
Menon AR, Cheema A, Hou S, Attwood KM, White T, James G, Xu B, Petroziello M, Roche CL, Kurenov S, and Kauffman EC
- Subjects
- Humans, Retrospective Studies, Kidney surgery, Kidney physiology, Kidney pathology, Glomerular Filtration Rate, Nephrectomy methods, Watchful Waiting, Kidney Neoplasms pathology
- Abstract
Introduction and Objective: To evaluate whether significant loss in ipsilateral renal parenchymal volume (IRPV) and renal function occurs during active surveillance (AS) of renal oncocytoma (RO) patients., Methods: Renal function (estimated glomerular filtration rate, eGFR) dynamics were retrospectively analyzed in 32 consecutive biopsy-diagnosed RO patients managed with AS at a National Comprehensive Cancer Network institute. Three-dimensional kidney and tumor reconstructions were generated and IRPV was calculated using volumetry software (Myrian®) for all patients with manually estimated RO growth >+10 cm
3 . GFR and IRPV were compared at AS initiation vs. the last follow-up using 2-sided paired t-tests. The correlation between change in IRPV and change in RO size or GFR was tested using a Spearman coefficient., Results: With median follow-up of 37 months, there was no significant change between initial vs. last eGFR (median 71.0 vs. 70.5 ml/min/1.73 m2 , P = 0.50; median change -3.0 ml/min/1.73 m2 ). Among patients (n = 17) with RO growth >+10 cm3 during AS (median growth +28.6 cm3 , IQR +16.9- + 46.5 cm3 ), IRPV generally remained stable (median change +0.5%, IQR -1.2%- + 1.2%), with only 2 cases surpassing 5% loss. No IRPV loss was detected among any patient within the top tertile of RO growth magnitude. RO growth magnitude did not correlate with loss of either IRPV (ρ = -0.30, P = 0.24) or eGFR (ρ = -0.16, P = 0.40), including among patient subsets with lower initial eGFR. Study limitations include a lack of long-term follow-up., Conclusions: Volumetry is a promising novel tool to measure kidney and tumor tissue changes during AS. Our study using volumetry indicates that clinically significant loss of IRPV or eGFR is uncommon and unrelated to tumor growth among untreated RO patients with intermediate follow-up. These findings support that AS is in general functionally safe for RO patients, however longer study is needed to determine safety durability, particularly among uncommon ≥cT2 RO variants., Competing Interests: Conflict of interest The authors report no potential conflicts of interest relevant to this study., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
10. Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C).
- Author
-
Goswami P, Adeniran OR, K Frantz S, Matsuoka L, Du L, Gandhi RT, Collins ZS, Matrana MR, Petroziello M, Brower JS, Sze DY, Kennedy AS, Golzarian J, Wang EA, and Brown DB
- Subjects
- Humans, Progression-Free Survival, Proportional Hazards Models, Cohort Studies, Carcinoma, Hepatocellular pathology, Liver Neoplasms pathology
- Abstract
Introduction: National Comprehensive Cancer Network HCC guidelines recommend Y90 to treat BCLC-C patients only in select cases given the development of systemic regimens. We sought to identify ideal candidates for Y90 by assessing survival and toxicities in this patient group., Materials and Methods: The Radiation-Emitting Selective Internal radiation spheres in Non-resectable tumor registry is a prospective observational study (NCT: 02,685,631). Patients with advanced HCC were stratified into 3 groups based on tumor location, Eastern Cooperative Oncology Group (ECOG) performance status, and liver function. Group 1: liver isolated HCC, ECOG 0 and Child Pugh (CP) A (n = 12, 16%), Group 2: liver isolated HCC, ECOG ≥ 1 or CP B/C (n = 37, 49%), and Group 3: extrahepatic HCC with any ECOG or CP score (n = 26, 35%). Patients in any group could have macrovascular invasion. Overall survival (OS) and progression-free survival (PFS) with 95% confidence intervals (95% CI) were calculated. Grade 3 + toxicities were tracked using Common Terminology Criteria for Adverse Events v5. Cox proportional hazard model was performed to determine factors affecting OS., Results: Seventy-five BCLC-C patients treated between 2015 and 2019 were reviewed. The groups were similar in age, sex, race, and ethnicity (all p > 0.05). Bilobar disease was least common in Group 1 (p < 0.001). Median OS of the entire cohort was 13.6 (95% CI 7.5-16.1) months. Median OS of Groups 1-3 were 21.8, 13.1 and 11.5 months respectively (p = 0.6). Median PFS for the cohort was 6.3 (4.8-14.7) months. Median PFS for group 1 was not reached. Mean PFS for Group 1 was 17.3 ± 4.8 months. Median PFS for Groups 2 and 3 was 6.8 and 5.9 months (X
2 = 1.5, p = 0.5). Twenty-four Grade 3 or greater toxicities developed, most commonly hyperbilirubinemia (8/75, 11%) and thrombocytopenia (2/75, 3%). The incidence of toxicities between groups was similar (all p > 0.05). Cox Proportional Hazard analysis predicted shorter OS with CP class B/C (X2 = 6.7, p = 0.01), while macrovascular invasion (X2 = 0.5, p = 0.5) and ECOG score of ≥ 1 (X2 = 2.1, p = 0.3) was not associated with OS., Conclusions: OS of CPA patients with advanced HCC and performance status of 0 was 21.8 months following Y90. CP A cirrhosis is the best predictor of prolonged OS in advanced (BCLC-C) HCC., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
11. Survival and Toxicities after 90 Y Transarterial Radioembolization of Metastatic Colorectal Cancer in the RESIN Registry.
- Author
-
Emmons EC, Bishay S, Du L, Krebs H, Gandhi RT, Collins ZS, O'Hara R, Akhter NM, Wang EA, Grilli C, Brower JS, Peck SR, Petroziello M, Abdel Aal AK, Golzarian J, Kennedy AS, Matsuoka L, Sze DY, and Brown DB
- Subjects
- Adult, Albumins, Bilirubin, Humans, Male, Microspheres, Middle Aged, Prospective Studies, Registries, Retrospective Studies, Treatment Outcome, Yttrium Radioisotopes therapeutic use, Colonic Neoplasms drug therapy, Embolization, Therapeutic methods, Liver Neoplasms secondary, Rectal Neoplasms therapy
- Abstract
Background Patients with unresectable, chemorefractory hepatic metastases from colorectal cancer have considerable mortality. The role of transarterial radioembolization (TARE) with yttrium 90 (
90 Y) microspheres is not defined because most reports are from a single center with limited patient numbers. Purpose To report outcomes in participants with colorectal cancer metastases treated with resin90 Y microspheres from a prospective multicenter observational registry. Materials and Methods This study treated enrolled adult participants with TARE using resin microspheres for liver-dominant metastatic colorectal cancer at 42 centers, with enrollment from July 2015 through August 2020. TARE was used as the first-, second-, or third-line therapy or beyond. Overall survival (OS), progression-free survival (PFS), and toxicity outcomes were assessed by line of therapy by using Kaplan-Meier analysis for OS and PFS and Common Terminology Criteria for Adverse Events, version 5, for toxicities. Results A total of 498 participants (median age, 60 years [IQR, 52-69 years]; 298 men [60%]) were treated. TARE was used in first-line therapy in 74 of 442 participants (17%), second-line therapy in 180 participants (41%), and third-line therapy or beyond in 188 participants (43%). The median OS of the entire cohort was 15.0 months (95% CI: 13.3, 16.9). The median OS by line of therapy was 13.9 months for first-line therapy, 17.4 months for second-line therapy, and 12.5 months for third-line therapy (χ2 = 9.7; P = .002). Whole-group PFS was 7.4 months (95% CI: 6.4, 9.5). The median PFS by line of therapy was 7.9 months for first-line therapy, 10.0 months for second-line therapy, and 5.9 months for third-line therapy (χ2 = 8.3; P = .004). TARE-attributable grade 3 or 4 hepatic toxicities were 8.4% for bilirubin (29 of 347 participants) and 3.7% for albumin (13 of 347). Grade 3 and higher toxicities were greater with third-line therapy for bilirubin ( P = .01) and albumin ( P = .008). Conclusion Median overall survival (OS) after transarterial radioembolization (TARE) with yttrium 90 microspheres for liver-dominant metastatic colorectal cancer was 15.0 months. The longest OS was achieved when TARE was part of second-line therapy. Grade 3 or greater hepatic function toxicity rates were less than 10%. Clinical trial registration no. NCT02685631 Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Liddell in this issue.- Published
- 2022
- Full Text
- View/download PDF
12. Active Surveillance for Risk Stratification of All Small Renal Masses Lacking Predefined Clinical Criteria for Intervention.
- Author
-
Menon AR, Hussein AA, Attwood KM, White T, James G, Xu B, Petroziello M, Roche CL, and Kauffman EC
- Subjects
- Biopsy, Disease Progression, Female, Humans, Kidney Neoplasms diagnostic imaging, Male, Middle Aged, Retrospective Studies, Time-to-Treatment, Kidney Neoplasms pathology, Risk Assessment, Watchful Waiting
- Abstract
Purpose: Despite general indolence of small renal masses and no known adversity from treatment delays, broad usage of active surveillance as a means to risk-stratify patients with small renal masses for more selective treatment has not been studied. We describe outcomes for a novel approach in which active surveillance was recommended to all patients with small renal masses lacking predefined progression criteria for intervention., Materials and Methods: All nondialysis dependent patients with nonmetastatic small renal masses seen by 1 urologist at a comprehensive cancer center during January 2013-September 2017 were managed with active surveillance if standardized progression criteria for intervention were absent, with delayed intervention recommended only upon progression criteria for intervention development. Progression criteria for intervention were defined prospectively as small renal mass-related symptoms, unfavorable histology, cT3a stage or either of the following without benign neoplastic biopsy histology: longest tumor diameter >4 cm; growth rate >5 mm/year for longest tumor diameter ≤3 cm or >3 mm/year for longest tumor diameter >3 cm., Results: In all, 96% (123/128) of patients with small renal masses lacked progression criteria for intervention at presentation and underwent active surveillance. With median/mean 31/34 months followup, none developed metastasis and 30% (37/123) developed progression criteria for intervention, 78% (29/37) of whom underwent delayed intervention. One (1%) patient crossed over to delayed intervention without progression criteria for intervention. Three-year progression criteria for intervention-free and delayed intervention-free rates were 72% and 75%, respectively. Delayed intervention resections were enriched (62%) for pT3 and/or nuclear grade 3-4 malignant pathology, with no benign resections., Conclusions: Active surveillance using predefined progression criteria for intervention in otherwise unselected patients with small renal masses allows intervention to be focused on at-risk small renal masses with common adverse pathology, avoiding treatment for most patients with small renal masses. Long-term delayed intervention and oncologic safety require study.
- Published
- 2021
- Full Text
- View/download PDF
13. Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry.
- Author
-
Frantz S, Matsuoka L, Vaheesan K, Petroziello M, Golzarian J, Wang E, Gandhi R, Collins Z, Brower J, Rachakonda VM, Du L, Kennedy AS, Sze DY, Lee J, and Brown DB
- Subjects
- Aged, Carcinoma, Hepatocellular diagnostic imaging, Carcinoma, Hepatocellular mortality, Disease Progression, Female, Humans, Liver Neoplasms diagnostic imaging, Liver Neoplasms mortality, Male, Microspheres, Middle Aged, Progression-Free Survival, Prospective Studies, Radioisotopes adverse effects, Radiopharmaceuticals adverse effects, Registries, Time Factors, Carcinoma, Hepatocellular radiotherapy, Embolization, Therapeutic adverse effects, Embolization, Therapeutic mortality, Liver Neoplasms radiotherapy, Radioisotopes administration & dosage, Radiopharmaceuticals administration & dosage
- Abstract
Purpose: To determine overall survival (OS), progression-free survival (PFS), and toxicity in patients with hepatocellular carcinoma (HCC) in a multicenter, real-world data registry using transarterial radioembolization (TARE) with resin microspheres., Materials and Methods: A total of 448 patients with HCC were treated at 36 centers between 2015 and 2019. Treatment history, baseline laboratory and imaging, and treatment goal were assessed. OS and PFS were stratified using Barcelona Clinic Liver Cancer (BCLC) and Child-Pugh (CP) classifications. Kaplan-Meier analyses compared OS and PFS with 95% confidence intervals. Transplants were tracked. Toxicities were assessed using Common Terminology Criteria for Adverse Events v5. Cox proportional hazard of baseline demographics assessed factors affecting survival., Results: Prior chemoembolization and systemic therapy were used in 107 (26%) and 68 (16%) patients, respectively. Using the BCLC staging system, 66 patients (19%) were BCLC A and 202, 51, and 26 were BCLC B, C, and D, respectively. Median OS for patients with BCLC A disease was not achieved at 30 months. Median OS for patients with BCLC B, C, and D disease were 19.5, 13.6, and 11.5 months, respectively (P = .0006). Median PFS for patients with BCLC A, B, C, and D were 19.8, 10.0, 6.3, and 5.9 months, respectively (P = .003). Twenty patients underwent transplantation, representing 14 of 43 (33%) and 6 of 28 (21%) patients who underwent bridging and downstaging therapy, respectively. Common Grade 3 toxicities were encephalopathy (11/448, 2.5%), hyperbilirubinemia (10/448, 2.2%), and ascites (9/448, 2.0%). Factors predicting longer survival included CP A (χ
2 = 4.2, P = .04) and BCLC A (χ2 = 5.2, P = .02)., Conclusions: In a frequently pretreated patient cohort with disease burden in 81% beyond the Milan criteria, TARE with resin microspheres provided OS comparable to other studies in this multicenter registry., (Copyright © 2021 SIR. Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
14. Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.
- Author
-
Amin J, Xu B, Badkhshan S, Creighton TT, Abbotoy D, Murekeyisoni C, Attwood KM, Schwaab T, Hendler C, Petroziello M, Roche CL, and Kauffman EC
- Subjects
- Adenoma, Oxyphilic genetics, Adenoma, Oxyphilic pathology, Adenoma, Oxyphilic surgery, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor genetics, Biopsy, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell pathology, Carcinoma, Renal Cell surgery, Cell Differentiation genetics, Cohort Studies, Female, Humans, Kidney pathology, Kidney Neoplasms genetics, Kidney Neoplasms pathology, Kidney Neoplasms surgery, Male, Middle Aged, Neoplasms genetics, Neoplasms pathology, Neoplasms surgery, Nephrectomy, Proto-Oncogene Proteins c-kit genetics, Retrospective Studies, Adenoma, Oxyphilic diagnosis, Carcinoma, Renal Cell diagnosis, Diagnosis, Differential, Kidney Neoplasms diagnosis, Neoplasms diagnosis
- Abstract
Purpose: The diagnostic differential for CD117/KIT(+) oncocytic renal tumor biopsies is limited to benign renal oncocytoma versus chromophobe renal cell carcinoma (ChRCC); however, further differentiation is often challenging and requires surgical resection. We investigated clinical variables that might improve preoperative differentiation of CD117(+) renal oncocytoma versus ChRCC to avoid the need for benign tumor resection. Experimental Design: A total of 124 nephrectomy patients from a single institute with 133 renal oncocytoma or ChRCC tumors were studied. Patients from 2003 to 2012 comprised a retrospective cohort to identify clinical/radiographic variables associated with renal oncocytoma versus ChRCC. Prospective validation was performed among consecutive renal oncocytoma/ChRCC tumors resected from 2013 to 2017. Results: Tumor size and younger age were associated with ChRCC, and multifocality with renal oncocytoma; however, the most reliable variable for ChRCC versus renal oncocytoma differentiation was the tumor:cortex peak early-phase enhancement ratio (PEER) using multiphase CT. Among 54 PEER-evaluable tumors in the retrospective cohort [19 CD117(+), 13 CD117(-), 22 CD117-untested], PEER classified each correctly as renal oncocytoma (PEER >0.50) or ChRCC (PEER ≤0.50), except for four misclassified CD117(-) ChRCC variants. Prospective study of PEER confirmed 100% accuracy of renal oncocytoma/ChRCC classification among 22/22 additional CD117(+) tumors. Prospective interobserver reproducibility was excellent for PEER scoring (intraclass correlation coefficient, ICC = 0.97) and perfect for renal oncocytoma/ChRCC assignment (ICC = 1.0). Conclusions: In the largest clinical comparison of renal oncocytoma versus ChRCC to our knowledge, we identified and prospectively validated a reproducible radiographic measure that differentiates CD117(+) renal oncocytoma from ChRCC with potentially 100% accuracy. PEER may allow reliable biopsy-based diagnosis of CD117(+) renal oncocytoma, avoiding the need for diagnostic nephrectomy. Clin Cancer Res; 24(16); 3898-907. ©2018 AACR ., (©2018 American Association for Cancer Research.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.